Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307461 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
A Phase 1 study of Healthy, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT02307461 is a Phase 1 study of Healthy that has completed, run by SecuraBio. The registered enrollment target is 103 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02307461, a Phase 1 study of Healthy, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on the Pharmacokinetics of IPI-145
Conditions Studied
Interventions
- DRUG IPI-145
- DRUG IPI-145 (duvelisib)
Study Locations (1)
Kansas
- - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02307461
The ClinicalTrials.gov registry entry for NCT02307461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower). The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which IPI-145 is the first listed.
NCT02307461 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02307461 about?
NCT02307461 is a clinical study titled "Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145". To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on the Pharmacokinetics of IPI-145
What is the current status of trial NCT02307461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2014-11. Estimated completion is 2015-09.
What conditions does trial NCT02307461 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02307461?
The interventions under investigation include: IPI-145 (DRUG), IPI-145 (duvelisib) (DRUG).
Who is sponsoring clinical trial NCT02307461?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02307461 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.